Sharing the Results: ALKS 3831

Adam Simmons, MPH

ALKS 3831, if approved by the FDA, could be a promising new treatment option for schizophrenia or bipolar I disorder.

Adam Simmons, MPH, shares results and insights from the Enlightened II study for Alkermes' drug, ALKS 3831.

To read more about ALKS 3831, see FDA Advisory Committee Votes in Favor of ALKS 3831.

Mr Simmons is the Director of Clinical Program Management at Alkermes.